B-cell lymphoma recurrent

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
3 Unique sponsors
3 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
CAR-T cell therapy 1 substance
Phase II: 3 Phase I/II: 1 Phase I: 2

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

3 trials
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-506270-13-00 15 countries 2021 n=223 Orphan
    Ended
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-506348-17-00 4 countries 2025 n=12 Orphan
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    ZAMTOCABTAGENE AUTOLEUCEL
    2023-508508-39-01 2 countries n=4
    Pending

Phase I/II

1 trial
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19; MB-CART20.1; ZAMTOCABTAGENE AUTOLEUCEL
    2022-501648-14-00 1 country 2024 n=40 Orphan
    Recruiting

Phase I

2 trials
  • Immunome Inc. Commercial
    IMP not specified
    2025-523160-20-00 4 countries 2026 n=41
    Recruiting
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Miltenyi Biomedicine GmbH Commercial 4 Phase II, Phase I/II 2
Immunome Inc. Commercial 1 Phase I 1
Ubix Therapeutics Inc. Commercial 1 Phase I 0
New trials by year
2021
1
2024
1
2025
1
2026
1
← All indication landscapes